Maria Betty Grace Bontigao-Emocling: 7 Years of Purpose-Driven Leadership at Boehringer Ingelheim
Maria Betty Grace Bontigao-Emocling, Therapeutic Area Lead – Cardiovascular and Lytics Business at Boehringer Ingelheim, shared a post on LinkedIn:
”Celebrating 7 years at Boehringer Ingelheim today-and feeling incredibly proud of the journey.
Over the years, I’ve been entrusted to lead and contribute across cardiovascular, respiratory, specialty care, rare disease, and now thrombosis care.
Each therapeutic area brought new challenges, deeper responsibility, and the opportunity to grow as a leader.
I’m grateful for leaders who believed in me, mentors who challenged me, and teammates who consistently show what excellence and collaboration look like. It’s an honor to help shape patient journeys and work alongside passionate key opinion leaders who share the same purpose.
Most proud to be leading a dynamic, resilient, and high‑performing One Stroke Care Team-a group driven by impact, teamwork, and commitment to patients.
Looking forward to more milestones, growth, and meaningful impact in the years ahead.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome